Similar articles

• BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.

  Jin L, Chen E, Dong S, Cai Y, Zhang X, Zhou Y, Zeng R, Yang F, Pan C, Liu Y, Wu W, Xing M, Zhang X, Wang O. Jin L, et al. Oncotarget. 2016 Apr 5;7(14):18346-55. doi: 10.18632/oncotarget.7811. Oncotarget. 2016. PMID: 26943032 Free PMC article.
• Co-existence of BRAF^V600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis.

  Ren H, Shen Y, Hu D, He W, Zhou J, Cao Y, Mao Y, Dou Y, Xiong W, Xiao Q, Zhang Y, Su X. Ren H, et al. Cancer Manag Res. 2018 May 3;10:1005-1013. doi: 10.2147/CMAR.S159583. eCollection 2018. Cancer Manag Res. 2018. PMID: 29760568 Free PMC article.
• TERT mRNA Expression as a Novel Prognostic Marker in Papillary Thyroid Carcinomas.

  Tanaka A, Matsuse M, Saenko V, Nakao T, Yamanouchi K, Sakimura C, Yano H, Nishihara E, Hirokawa M, Suzuki K, Miyauchi A, Eguchi S, Yoshiura KI, Yamashita S, Nagayasu T, Mitsutake N. Tanaka A, et al. Thyroid. 2019 Aug;29(8):1105-1114. doi: 10.1089/thy.2018.0695. Epub 2019 Aug 5. Thyroid. 2019. PMID: 31286848
• Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis.

  Vuong HG, Altibi AMA, Duong UNP, Hassell L. Vuong HG, et al. Clin Endocrinol (Oxf). 2017 Nov;87(5):411-417. doi: 10.1111/cen.13413. Epub 2017 Aug 2. Clin Endocrinol (Oxf). 2017. PMID: 28666074 Review.
• TERT promoter mutations in thyroid cancer.

  Matsuse M, Mitsutake N. Matsuse M, et al. Endocr J. 2023 Nov 28;70(11):1035-1049. doi: 10.1507/endocrj.EJ23-0136. Epub 2023 Aug 1. Endocr J. 2023. PMID: 37532521 Review.